Intercept Pharmaceuticals, Inc. May 22, 2023 Join Investigation Principle Contacts Jeffrey P. Campisi JCampisi@kaplanfox.com NEW YORK, NY – May 22, 2023 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) securities. Click Here To Join Investigation. If you purchased Intercept securities and would like to discuss our investigation, please click here, or contact us by emailing jcampisi@kaplanfox.com or calling (212) 329-8571. On May 19, 2023, Intercept announced the outcome of the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) Meeting to review the Company’s New Drug Application (NDA) for obeticholic acid (OCA) for the treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH). Twelve of 16 voting-eligible GIDAC members voted “no” (with two abstentions) on the voting question, “given the available efficacy and safety data, do the benefits of OCA 25 mg outweigh the risks in NASH patients with stage 2 or 3 fibrosis?” Fifteen of 16 voting-eligible GIDAC members (with no abstentions) voted to “defer approval until clinical outcome data from trial 747-303 are submitted and reviewed, at which time the traditional approval pathway could be considered.” On May 18, 2023, trading of Intercept’s shares on Nasdaq were halted at $13.56 per share in advance of the GIDAC meeting. WHY CONTACT KAPLAN FOX – Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this investigation, please contact: Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(212) 329-8571E-mail: jcampisi@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704Fax: (415) 772-4707E-mail: lking@kaplanfox.com Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Integra LifeSciences Holdings Corporation See the Case Eos Energy Enterprises, Inc. See the Case Shift4 Payments, Inc. See the Case Hawaiian Electric Industries, Inc. See the Case Masimo Corporation See the Case Hayward Holdings, Inc. See the Case NAPCO Security Technologies, Inc. See the Case Blink Charging Co. See the Case Sea Limited See the Case Baxter International, Inc. See the Case RTX Corporation See the Case BioXcel Therapeutics, Inc. See the Case
